DKK2 blockage-mediated immunotherapy enhances anti-angiogenic therapy of Kras mutated colorectal cancer

There are limited options for targeted therapies for colorectal cancer (CRC). Anti-EGFR therapy is limited to CRC without KRAS mutations. Even worse, most of CRC are refractory to currently immune checkpoint blockade. DKK2, which is upregulated in CRC, was recently found to suppress host immune resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiajia, Wang, Zhengting, Chen, Zhengxi, Li, Ao, Sun, Jing, Zheng, Minhua, Wu, Jibo, Shen, Tianli, Qiao, Ju, Lin, Li, Li, Biao, Wu, Dianqing, Xiao, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523634/
https://www.ncbi.nlm.nih.gov/pubmed/32559853
http://dx.doi.org/10.1016/j.biopha.2020.110229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523634/
https://www.ncbi.nlm.nih.gov/pubmed/32559853
http://dx.doi.org/10.1016/j.biopha.2020.110229

Ejemplares similares